First patient administered by Tenaya Therapeutics in MyPeak-1™ Phase 1b Clinical Trial for TN-201 treatment to address MYBPC3-Associated Hypertrophic Cardiomyopathy.

Janus kinase inhibitor, often referred to as JAKi, is a type of oral small molecule chemically synthesized drug.

The Swiss pharmaceutical giant Roche has seen sluggish growth in its oncology division, with almost no increase in four years, worsened further by the weakening of the diagnostic division due to the COVID-19 pandemic.

This article summarized the latest R&D progress of inositol nicotinate, the Mechanism of Action for inositol nicotinate, and the drug target R&D trends for inositol nicotinate.

Oncternal Therapeutics starts administrating the first dose in phase 1/2 trial of ONCT-534, a dual-action AR inhibitor, for metastatic castration-resistant prostate cancer patients.

Neprilysin, also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10), and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene.

Janssen applies to the European Medicines Agency, seeking approval for using RYBREVANT (amivantamab) combined with chemotherapy to treat adults initially diagnosed with late-stage Non-Small Cell Lung Cancer with proficient EGFR Exon 20 Insertion Mutations.

This article summarized the latest R&D progress of interferon beta-1b, the Mechanism of Action for interferon beta-1b, and the drug target R&D trends for interferon beta-1b.

Since acquiring Allergan, AbbVie has experienced a period of stable performance, but this year has seen a significant decline in the performance of its two heavyweight drugs, Adalimumab and Ibrutinib.

This article summarized the latest R&D progress of itopride hydrochloride, the Mechanism of Action for itopride hydrochloride, and the drug target R&D trends for itopride hydrochloride

The 2a trial of Rivus Pharmaceuticals' experimental metabolic booster, HU6, yielded promising results in treating High BMI individuals with Non-alcoholic Fatty Liver Disease.

This article summarized the latest R&D progress of laquinimod, the Mechanism of Action for laquinimod, and the drug target R&D trends for laquinimod.